Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Status Active, not recruiting

Clinical Trial Summary

The aim of this study is to evaluate the safety profile of Dengvaxia® when used in the real-world immunization setting Primary Objective: - To measure the incidence of selected adverse events (AEs) and serious AEs (SAEs) occurring over a period of six (6) months after each Dengvaxia® dose administration; - To quantify the association between Dengvaxia® and each of the selected AEs and SAEs for which a risk window after vaccination can be defined, using estimates of relative risk - To monitor the occurrence and frequency of hospitalized dengue disease as well as any other SAEs leading to hospitalization or death, including new and previously unrecognized SAEs, following Dengvaxia® administration on a longer term (up to 5 years after the first Dengvaxia® dose administration. Secondary objectives: - To identify risk factors for hospitalized dengue disease (severe or not) among subjects vaccinated with Dengvaxia®; - To describe the frequency of hospitalized dengue disease and/or other SAEs or selected AEs according to the number of Dengvaxia® doses and/or interval between doses.

Clinical Trial Description

This is a prospective multi-national non-interventional study that includes two components of Cohort Event Monitoring (i) Short-term safety surveillance with a follow-up of 6 months after each Dengvaxia® dose administration and (ii) a long-term safety surveillance with a follow-up of five years after the first dose. No vaccine will be provided as part of this study. Study population will be identified in a convenient sample of sites as representative as possible of vaccination centers in each country. Subjects who received their first dose of Dengvaxia® at participating sites during the recruitment period and who meet the eligibility criteria will be asked to participate. After enrollment, vaccinees will be contacted periodically by telephone, e-mail, or Short Message Service (SMS) during follow-up for the identification of outcomes and Dengvaxia® vaccination status. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02948933
Study type	Observational
Source	Sanofi
Contact
Status	Active, not recruiting
Phase
Start date	December 14, 2016
Completion date	July 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04514107` - A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)	Phase 2
Completed	`NCT00788151` - Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years	Phase 2
Completed	`NCT02510638` - The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia	N/A
Completed	`NCT01666652` - A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults	Phase 1
Completed	`NCT01477671` - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children	N/A
Completed	`NCT01443247` - Role of Andi-d in Dengue Fever: a Pilot Study	N/A
Completed	`NCT00831012` - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults	Phase 1
Completed	`NCT00089908` - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults	Phase 1
Completed	`NCT01983553` - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed	`NCT01134263` - Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia	Phase 3
Completed	`NCT02741128` - Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults	Phase 2
Completed	`NCT03620487` - Detection of Dengue Virus in Plasma of Patients in Nepal
Recruiting	`NCT02608047` - Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou	N/A
Completed	`NCT02510690` - Factors Associated With Poor Dengue Outcomes in Malaysia	N/A
Completed	`NCT01550016` - International Research Consortium on Dengue Risk Assessment, Management, and Surveillance	N/A
Completed	`NCT01421732` - Laboratory Diagnosis and Prognosis of Severe Dengue	N/A
Completed	`NCT00993447` - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America	Phase 2
Completed	`NCT01224639` - Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever	Phase 1
Completed	`NCT01943825` - Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine	Phase 2
Active, not recruiting	`NCT03465254` - Dengue Serostatus Study in the Philippines

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.